Regional leadership Egis is a leading generic pharmaceutical player in Central Eastern Europe with a broad regional footprint across 18 countries and 100 countries reachable through subsidiaries and partners, indicating substantial cross-border sales opportunities and potential for distribution partnerships.

Biosimilar portfolio Since launching the first EU biosimilar monoclonal antibody and three additional biosimilars, Egis demonstrates capability and market-ready products in high-value biologics, suggesting opportunities to collaborate on biosimilar development, licensing, or contract manufacturing for biologics.

R&D and innovation With substantial annual R&D investment and modernized manufacturing and R&D centers, Egis presents opportunities to co-develop branded generics or specialized formulations, as well as potential technology licensing or joint development agreements.

Strategic expansions Recent plant expansions in Körmend and advanced packaging capabilities, plus the launch of a new line of business for contract development and manufacturing, create avenues for contract manufacturing, supply capacity expansion, and strategic partnerships in manufacturing and supply chain services.

People and prestige Recognition as a top employer and attractive life sciences employer in Hungary highlights strong talent, potential for partnerships around training, clinical support, and blended services, and reinforces credibility when engaging with regional healthcare and hospital systems.